Adding Atezolizumab to mFOLFOX6 Improves DFS Among Patients with Stage III dMMR Colon Cancer By Ogkologos - March 31, 2026 165 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATOMIC study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up August 5, 2025 Research shows one size doesn’t fit all for cervical screening in... May 17, 2021 FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell... July 22, 2026 A Meaningful Benefit of the Quadruplet-Based Isatuximab Plus VRd Regimen in... July 11, 2024 Load more HOT NEWS Study Links Breast Cancer Spread to Newly Discovered RNA Splicing Mechanism Man Pushes Daughter To Safety Before Speeding Car Hits Him Instead:... Durable Activity of Repotrectinib in Patients with ROS1 Fusion–Positive NSCLC Regardless... Mom Wants Disney To Ban Childless Adults From Their Theme Parks
